From Screening to Treatment: Technology’s Impact on Breast Cancer Care

A special issue of Current Oncology (ISSN 1718-7729). This special issue belongs to the section "Breast Cancer".

Deadline for manuscript submissions: 31 January 2025 | Viewed by 473

Special Issue Editor


E-Mail Website
Guest Editor
1. Department of Medicine, Academy of Applied Medical and Social Sciences, Akademia Medycznych I Spolecznych Nauk Stosowanych (AMiSNS), 2 Lotnicza Street, 82-300 Elbląg, Poland
2. Department of General Surgery and Surgical Oncology, “Saint Wojciech” Hospital, “Nicolaus Copernicus” Health Center, Jana Pawła II 50, 80-462 Gdańsk, Poland
Interests: breast cancer surgery; artificial intelligence; virtual reality in surgery

Special Issue Information

Dear Colleagues,

This Special Issue will uncover the transformative impact of new technologies, virtual reality (VR), and artificial intelligence (AI) across the development of breast cancer care. It will explore advancements in screening methods such as digital mammography and AI-powered image interpretation, alongside diagnostic innovations including AI-driven biopsy guidance and personalized risk stratification. Histopathological improvements through digital pathology and AI-enabled image analysis will be discussed, as well as surgical interventions enhanced by augmented reality (AR) and robotics. Additionally, the role of AI and AR in elucidating genetic and environmental risk factors for breast cancer will be explored. These innovations aim to optimize treatment strategies, from radiotherapy planning to targeted drug delivery, ultimately opening up a new era of precision oncology and personalized patient care. Ethical considerations regarding data privacy and equity will also be addressed, highlighting the need for collaborative efforts to navigate the ethical and societal implications of these advancements. Additionally, this Special Issue will highlight the collaborative efforts of diverse specialties, emphasizing a transdisciplinary approach to address the multifaceted challenges of breast cancer. By integrating cutting-edge technologies and fostering interdisciplinary collaboration, this Special Issue will pave the way for a comprehensive and patient-centered approach to breast cancer management.

I look forward to hearing from you.

Dr. Jaroslaw Skokowski
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Dr. Jaroslaw Skokowski
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • breast cancer
  • technology
  • artificial intelligence (AI)
  • virtual reality (VR)
  • screening
  • diagnosis
  • digital pathology
  • robotic mastectomy
  • precision oncology
  • transdisciplinary collaboration

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

10 pages, 228 KiB  
Article
A Retrospective Analysis of Diagnostic Breast Imaging Outcomes in Young Women at a Tertiary Care Center
by Navdeep Dehar, Doris Jabs, Wilma Hopman and Mihaela Mates
Curr. Oncol. 2024, 31(7), 3939-3948; https://doi.org/10.3390/curroncol31070291 - 6 Jul 2024
Viewed by 344
Abstract
(1) Purpose: The purpose of this study was to describe the outcomes of diagnostic breast imaging and the incidence of delayed breast cancer diagnosis in the study population. (2) Methods: We collected the outcome data from diagnostic mammograms and/or breast ultrasounds (USs) performed [...] Read more.
(1) Purpose: The purpose of this study was to describe the outcomes of diagnostic breast imaging and the incidence of delayed breast cancer diagnosis in the study population. (2) Methods: We collected the outcome data from diagnostic mammograms and/or breast ultrasounds (USs) performed on women between the ages of 30 and 50 with symptomatic breast clinical presentations between 2018 and 2019. (3) Results: Out of 171 eligible patients, 10 patients (5.8%) had BIRADS 0, 90 patients (52.6%) had benign findings (BIRADS 1 and 2), 41 (24.0%) patients had probable benign findings requiring short-term follow-up (BIRADS 3), while 30 (17.5%) patients had findings suspicious of malignancy (BIRADS 4 and 5). In the BIRADS 3 group, 92.7% had recommended follow-up, while in BIRADS 4 and 5, only 83.3% underwent recommended biopsy at a mean time of 1.7 weeks (range 0–22 wks) from their follow-up scan. Ten (6%) patients were diagnosed with breast cancer, all of whom had BIRADS 4 or 5, with a mean time of breast cancer diagnosis from initial diagnostic imaging of 2.2 weeks (range 1–22 wks). No patients had delayed breast cancer diagnosis in our cohort. (4) Conclusions: We conclude that diagnostic mammograms and breast US are appropriate investigations for clinical breast concerns in women aged 30–50 years. Full article
Back to TopTop